BioLineRx - BLRX Stock Forecast, Price & News

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on BioLineRx in a research note on Monday, August 1st. They issued a "hold" rating on the stock.

BioLineRx Stock Up 9.4 %

BioLineRx stock traded up $0.15 during trading on Friday, hitting $1.74. The stock had a trading volume of 290,898 shares, compared to its average volume of 88,575. BioLineRx has a 1 year low of $1.01 and a 1 year high of $3.18. The stock's 50 day moving average is $1.38 and its two-hundred day moving average is $1.49. The stock has a market cap of $83.33 million, a price-to-earnings ratio of -3.11 and a beta of 1.92.

BioLineRx (NASDAQ:BLRX - Get Rating) last posted its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.05. As a group, equities research analysts anticipate that BioLineRx will post -0.51 EPS for the current fiscal year.